Sareum Holdings PLC on Friday said it received a notice of allowance from Japan’s Patent Office for a patent relating to its lead TYK2/JAK1 kinase inhibitor, SDC-1801.
The Cambridge, England-based pharmaceutical company said the Japanese patent, Special Application 2021-543577, ‘safeguards SDC-1801 and its medical applications in treating inflammatory or immune disorders.’
Sareum expects the patent to be granted in the ‘near future,’ subject to ‘certain formalities being completed.
This comes after Sareum announced the granting of a patent for SDC-1801 in China earlier this year. Patent applications in Europe and the US are still under review, the company said.
SDC-1801 is being developed as a potential new therapeutic for a range of autoimmune diseases, with an initial focus on skin condition psoriasis, which affects over 60 million adults worldwide.
Chief Executive Officer John Reader said: ’The recent notice of allowance from the Japan Patent Office bolsters our growing confidence in SDC-1801, our lead TYK2/JAK1 kinase inhibitor. Our Phase 1a clinical trial in Australia is progressing well, and this latest patent recognition in Japan supports our intellectual property around this programme.‘
Shares in Sareum grew 1.9% to 58.60 pence each in London on Friday morning.
Copyright 2023 Alliance News Ltd. All Rights Reserved.
